View Future GrowthLavipharm 과거 순이익 실적과거 기준 점검 2/6Lavipharm은 연평균 29.5%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.8% 증가했습니다. 매출은 연평균 9.6%의 비율로 증가했습니다. Lavipharm의 자기자본이익률은 9.2%이고 순이익률은 8%입니다.핵심 정보29.48%순이익 성장률-35.63%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률9.56%자기자본이익률9.18%순이익률8.02%다음 순이익 업데이트17 Sep 2026최근 과거 실적 업데이트Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).모든 업데이트 보기Recent updatesNew Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Board Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Lavipharm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:BXA0 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 2665523031 Dec 2563523030 Sep 2555221130 Jun 2555221131 Mar 2552921131 Dec 2453921130 Sep 2446918030 Jun 2447819031 Mar 2452219031 Dec 2348218030 Sep 2354016130 Jun 2344116131 Mar 2349116131 Dec 2239115130 Sep 224324030 Jun 2241115131 Mar 2241112131 Dec 2140215130 Sep 2139215130 Jun 2139314131 Mar 2138214131 Dec 2038214130 Sep 2037414130 Jun 2036714131 Mar 2035614131 Dec 1934514130 Sep 1934314130 Jun 1934114131 Mar 1934115131 Dec 1834115130 Sep 1833016130 Jun 1832-116131 Mar 1832616131 Dec 17321315230 Sep 17321117230 Jun 17321018231 Mar 1732718231 Dec 1631418330 Sep 1631418330 Jun 1628415331 Mar 1627-215331 Dec 1526-715330 Sep 1527-915430 Jun 1529-9174양질의 수익: BXA0는 고품질 수익을 보유하고 있습니다.이익 마진 증가: BXA0의 현재 순 이익률 (8%)은 지난해 (16.3%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BXA0의 수익은 지난 5년 동안 연평균 29.5%로 크게 증가했습니다.성장 가속화: BXA0은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: BXA0은 지난 1년 동안 수익이 감소(-39.7%)하여 Pharmaceuticals 업계 평균(15.3%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: BXA0의 자본 수익률(9.2%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 14:37종가2026/06/16 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lavipharm S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).
New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).
공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).
New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.
Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.